A Phase 3 interventional study of Placebo and Relamorelin in Gastroparesis and Diabetes Mellitus, sponsored by Allergan. Terminated at 240 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-06.
Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 184 studies in Gastroparesis with a site in United States — 33 open to participants now, 41 under way, 2 of them phase 3. Gastroparesis · United States.
Among the 184 studies in Gastroparesis with a site in United States, this one is the 11th largest by enrollment of the 136 interventional ones that give a count, is one of 12 that started in 2018, is one of 12 in phase 3, and was the 91st registered.
323 studies on the registry are indexed under Gastroparesis; 75 are open to participants now.
Browse Gastroparesis studies →33 of the 184 studies in Gastroparesis with a site in United States are open now. Recruiting first, the newest first:
Evan (Huiliang) Wang · Sites in United States
Ages 18–70
Indiana University · Sites in United States
Ages 18+
Ohio State University · Sites in United States
Ages 18+
Ohio State University · Sites in United States
Ages 18–65
Viral N. Shah · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 49 Gastroparesis studies recruiting now, 25 (51%) set no upper age limit and 14 (29%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
184 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 42 · Phase 3 14 · Phase 4 6
First in 2002; this study’s year is marked. 12 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 311 is above the median of 42 across 215 interventional studies indexed under Gastroparesis.
Median enrollment 36 across the 136 interventional studies, 108 across the 39 observational. Of the 124 that completed or were terminated, 63 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
55 of 184 have an industry lead sponsor. The 10 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
AbbVie has 7 studies filed under Gastroparesis — fewer than ten, so there is no comparison to draw.
14 of the studies in Gastroparesis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01696734Phase 3M.D. Anderson Cancer CenterDomperidone in Treating Patients With Gastrointestinal Disorders | 2027-10-31 |
| NCT04506593Indiana UniversityIndiana University Gastrointestinal Motility Diagnosis Registry | 2026-11 |
| NCT06046833Samita GargContinuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes | 2026-12 |
| NCT02165059Indiana UniversityGI Neuromuscular Pathology Prospective Registry | 2026-12 |
| NCT04282317Indiana UniversityMagnetic Resonance Imaging of the Brain and Stomach in Healthy Volunteers and Gastroparesis | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 184 studies in Gastroparesis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety and efficacy of relamorelin compared to placebo in participants with diabetic gastroparesis. Participants will report daily severity scores of their diabetic gastroparesis symptoms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Following a 2-week placebo run-in, participants received placebo-matching relamorelin injected subcutaneously twice daily for up to 12 weeks.
Drug: Placebo
Following a 2-week placebo run-in, participants received relamorelin 10 micrograms (μg) injected subcutaneously twice daily for up to 12 weeks.
Drug: Relamorelin
Placebo injected subcutaneously twice daily.
Relamorelin 10 μg injected twice daily for 12 weeks.
Change From Baseline to Week 12 in the Weekly Diabetic Gastroparesis Symptom Severity Score (DGSSS)
Participants assessed the severity of diabetic gastroparesis symptoms daily using the Diabetic Gastroparesis Symptom Severity Diary (DGSSD), recorded in an electronic diary (e-diary). The DGSSS was derived as the sum of the weekly averages of the 4 DGSSD items: nausea, abdominal pain, postprandial fullness and bloating. Each symptom was scored using an 11-point ordinal scale where: 0= no or not at all uncomfortable to 10= worst possible or most uncomfortable for a total possible DGSSS of 0 (best) to 40 (worst). A negative change from Baseline indicates improvement. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period.
Time frame: Baseline (Day-14 to Day-1) to Week 12
Percentage of Participants Meeting the Vomiting Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period
The number of vomiting episodes in the previous 24 hours were assessed daily by the participant using the DGSSD and were recorded in the e-diary. A Vomiting Responder was defined as a participant with zero weekly vomiting episodes during each of the last 6 weeks of the 12-week Treatment Period.
Time frame: Week 6 to Week 12
Percentage of Participants Meeting the Nausea Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period
A Nausea Responder was defined as a participant with improvement (decrease) of at least 2-points in the weekly symptom scores for nausea at each of the last 6 weeks of the 12-week Treatment Period. Nausea was one of the items of the DGSSD assessed daily and recorded in the e-diary by the participant using an 11-point ordinal scale where: 0= no nausea to 10= worst possible nausea.
Time frame: Baseline (Day-14 to Day-1) to (Week 6 to Week 12)
Percentage of Participants Meeting the Abdominal Pain Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period
An Abdominal Pain Responder was defined as a participant with an improvement (decrease) of at least 2-points in the weekly symptom scores for abdominal pain at each of the last 6 weeks of the 12-week Treatment Period. Abdominal pain was one of the items of the DGSSD assessed daily and recorded in the e-diary by the participant using an 11-point ordinal scale where: 0= no abdominal pain to 10= the worst possible abdominal pain and was recorded in an e-diary.
Time frame: Baseline (Day-14 to Day-1) to (Week 6 to Week 12)
Percentage of Participants Meeting the Bloating Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period
A Bloating Responder was defined as a participant with an improvement (decrease) of at least 2-points in the weekly symptom scores for bloating at each of the last 6 weeks of the 12-week Treatment Period. Bloating was one of the items of the DGSSD assessed daily and recorded by the participant in the e-diary using an 11-point ordinal scale where: 0= no bloating and 10= the worst possible bloating and was recorded in the e-diary.
Time frame: Baseline (Day-14 to Day-1) to (Week 6 to Week 12)
Percentage of Participants Meeting the Postprandial Fullness Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period
A Postprandial Fullness Responder was defined as a participant with an improvement (decrease) of at least 2-points in the weekly symptom scores for Postprandial Fullness at each of the last 6 weeks of the 12-week Treatment Period. Postprandial Fullness was one of the items of the DGSSD assessed daily and recorded by the participant in the e-diary using an 11-point ordinal scale where: 0= no feeling of fullness until finishing a meal (best) to 10= feeling full after only a few bites (worst).
Time frame: Baseline (Day-14 to Day-1) to (Week 6 to Week 12)
Number of Participants Who Experienced One or More Treatment-Emergent Adverse Events (TEAE)
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE is an AE that begins or worsens after receiving study drug.
Time frame: Up to approximately 16 weeks
Number of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results
Clinical Laboratory tests included Hematology, Chemistry and Urinalysis tests. The investigator determined if the results were clinically significant. Only those categories where at least 1 person had a non-PCS value at Baseline and met the PCS criterion at least once during postbaseline are reported.
Time frame: Up to 12 weeks
Number of Participants With Clinically Meaningful Trends for Vital Signs
Vital Signs included assessments of heart rate, respiratory rate, systolic and diastolic blood pressure, and body temperature. The investigator determined if the abnormal results were clinically significant.
Time frame: Up to 12 weeks
Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Results
A standard 12-lead ECG was performed. The investigator determined if the abnormal results were clinically significant.
Time frame: Up to 12 weeks
Number of Participants With a ≥1% Increase in Glycosylated Hemoglobin A1c (HBA1c)
Time frame: Baseline (Day 1) up to 12 weeks
Number of Participants With Anti-relamorelin Antibody Testing Results by Visit
A blood sample was collected that was sent to a laboratory for an anti-relamorelin antibody screening test. A positive screening test was confirmed by an immunodepletion assay. The number of participants in each of the following categories are reported: Negative Screening Test, Positive Screening Test, Negative Confirmatory Test, and Positive Confirmatory Test at each time point.
Time frame: Baseline (Day 1), Day 14, Day 28, Day 84, and End of Treatment (Up to Day 84)
| Milestone | Placebo | Relamorelin 10 μg |
|---|---|---|
| Started | 155 | 156 |
| Safety population | 152 | 155 |
| Completed | 137 | 139 |
| Not completed | 18 | 17 |
| Withdrew: Adverse event | 4 | 4 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Withdrawal by subject | 5 | 6 |
| Withdrew: Lost to follow-up | 3 | 1 |
| Withdrew: Protocol deviation | 3 | 4 |
| Withdrew: Reason not specified | 1 | 2 |
| Withdrew: Missing completion status | 1 | 0 |
Participants assessed the severity of diabetic gastroparesis symptoms daily using the Diabetic Gastroparesis Symptom Severity Diary (DGSSD), recorded in an electronic diary (e-diary). The DGSSS was derived as the sum of the weekly averages of the 4 DGSSD items: nausea, abdominal pain, postprandial fullness and bloating. Each symptom was scored using an 11-point ordinal scale where: 0= no or not at all uncomfortable to 10= worst possible or most uncomfortable for a total possible DGSSS of 0 (best) to 40 (worst). A negative change from Baseline indicates improvement. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period.
| score on a scale | Placebo | Relamorelin 10 μg |
|---|---|---|
| Baseline | 23.4 ± 5.40 | 24.9 ± 6.15 |
| Change from Baseline to Week 12 | -9.3 ± 10.21 | -10.2 ± 9.24 |
The number of vomiting episodes in the previous 24 hours were assessed daily by the participant using the DGSSD and were recorded in the e-diary. A Vomiting Responder was defined as a participant with zero weekly vomiting episodes during each of the last 6 weeks of the 12-week Treatment Period.
| percentage of participants | Placebo | Relamorelin 10 μg |
|---|---|---|
| Percentage of Participants Meeting the Vomiting Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period | 19.1 | 18.7 |
A Nausea Responder was defined as a participant with improvement (decrease) of at least 2-points in the weekly symptom scores for nausea at each of the last 6 weeks of the 12-week Treatment Period. Nausea was one of the items of the DGSSD assessed daily and recorded in the e-diary by the participant using an 11-point ordinal scale where: 0= no nausea to 10= worst possible nausea.
| percentage of participants | Placebo | Relamorelin 10 μg |
|---|---|---|
| Percentage of Participants Meeting the Nausea Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period | 32.9 | 38.1 |
An Abdominal Pain Responder was defined as a participant with an improvement (decrease) of at least 2-points in the weekly symptom scores for abdominal pain at each of the last 6 weeks of the 12-week Treatment Period. Abdominal pain was one of the items of the DGSSD assessed daily and recorded in the e-diary by the participant using an 11-point ordinal scale where: 0= no abdominal pain to 10= the worst possible abdominal pain and was recorded in an e-diary.
| percentage of participants | Placebo | Relamorelin 10 μg |
|---|---|---|
| Percentage of Participants Meeting the Abdominal Pain Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period | 27.0 | 36.1 |
A Bloating Responder was defined as a participant with an improvement (decrease) of at least 2-points in the weekly symptom scores for bloating at each of the last 6 weeks of the 12-week Treatment Period. Bloating was one of the items of the DGSSD assessed daily and recorded by the participant in the e-diary using an 11-point ordinal scale where: 0= no bloating and 10= the worst possible bloating and was recorded in the e-diary.
| percentage of participants | Placebo | Relamorelin 10 μg |
|---|---|---|
| Percentage of Participants Meeting the Bloating Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period | 27.0 | 31.6 |
A Postprandial Fullness Responder was defined as a participant with an improvement (decrease) of at least 2-points in the weekly symptom scores for Postprandial Fullness at each of the last 6 weeks of the 12-week Treatment Period. Postprandial Fullness was one of the items of the DGSSD assessed daily and recorded by the participant in the e-diary using an 11-point ordinal scale where: 0= no feeling of fullness until finishing a meal (best) to 10= feeling full after only a few bites (worst).
| percentage of participants | Placebo | Relamorelin 10 μg |
|---|---|---|
| Percentage of Participants Meeting the Postprandial Fullness Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period | 23.7 | 27.7 |
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE is an AE that begins or worsens after receiving study drug.
| Participants | Placebo | Relamorelin 10 μg |
|---|---|---|
| Number of Participants Who Experienced One or More Treatment-Emergent Adverse Events (TEAE) | 75 | 86 |
Clinical Laboratory tests included Hematology, Chemistry and Urinalysis tests. The investigator determined if the results were clinically significant. Only those categories where at least 1 person had a non-PCS value at Baseline and met the PCS criterion at least once during postbaseline are reported.
| Participants | Placebo | Relamorelin 10 μg |
|---|---|---|
| Eosinophils Absolute Cell Count [10^9/liter (L)]: >3×Upper Limit of Normal Value (ULN) | 0 | 1 |
| Hematocrit (RATIO): >1.1×ULN | 1 | 0 |
| Hematocrit (RATIO): <0.9×Lower Limit of Normal Value (LLN) | 4 | 4 |
| Hemoglobin [grams (g)/L]: <0.9×LLN | 2 | 5 |
| Lymphocytes Absolute Cell Count (10^9/L): <0.8×LLN | 1 | 3 |
| Mean Corpuscular Volume [femtoliter(fL)]: >1.1×ULN | 1 | 1 |
| Neutrophils Absolute Cell Count (10^9/L): >1.5×ULN | 0 | 1 |
| Neutrophils Absolute Cell Count (10^9/L): <0.8×LLN | 2 | 2 |
| Red Blood Cell Count (10^12/L): <0.9×LLN | 1 | 1 |
| Alanine Aminotransferase [Serum Glutamic Pyruvic Transaminase (SGPT)] [unit(U)/L]: >=3×ULN | 1 | 0 |
| Albumin (g/L): <0.9×LLN | 0 | 1 |
| Alkaline Phosphatase (U/L): >=3×ULN | 1 | 0 |
| Aspartate Aminotransferase [Serum Glutamic Oxaloacetic Transaminase (SGOT)] (U/L): >=3×ULN | 1 | 2 |
| Bicarbonate (HCO3) [millimoles (mmol)/L]: >1.1×ULN | 0 | 1 |
| Bicarbonate (HCO3) (mmol/L): <0.9×LLN | 1 | 0 |
| Blood Urea Nitrogen (mmol/L): >1.2×ULN | 15 | 3 |
| Chloride (mmol/L): <0.9×LLN | 2 | 0 |
| Cholesterol, Total, Fasting (mmol/L): >1.6×ULN | 2 | 1 |
| Creatinine [micromoles(μmol)/L]: >1.3×ULN | 8 | 7 |
| Glucose-Chemistry, Fasting (mmol/L): >2.5×ULN | 11 | 21 |
| Glucose-Chemistry, Fasting (mmol/L): <0.9×LLN | 6 | 5 |
| Glycohemoglobin A1C: Increase of >=0.5% | 80 | 111 |
| Glycohemoglobin A1C: Increase of >=1% | 80 | 111 |
| Phosphorus (mmol/L): >1.1×ULN | 5 | 5 |
| Phosphorus (mmol/L): <0.9×LLN | 1 | 1 |
| Potassium (mmol/L): <0.9×LLN | 1 | 0 |
| Sodium (mmol/L): <0.9×LLN | 1 | 0 |
| Triglycerides, Fasting (mmol/L): >=3×ULN | 3 | 5 |
| Uric Acid (Urate) (μmol/L): >1.1×ULN | 18 | 13 |
| Uric Acid (Urate) (μmol/L): <0.9×LLN | 3 | 0 |
Vital Signs included assessments of heart rate, respiratory rate, systolic and diastolic blood pressure, and body temperature. The investigator determined if the abnormal results were clinically significant.
| Participants | Placebo | Relamorelin 10 μg |
|---|---|---|
| Number of Participants With Clinically Meaningful Trends for Vital Signs | 0 | 0 |
A standard 12-lead ECG was performed. The investigator determined if the abnormal results were clinically significant.
| Participants | Placebo | Relamorelin 10 μg |
|---|---|---|
| Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Results | 1 | 2 |
| Participants | Placebo | Relamorelin 10 μg |
|---|---|---|
| Number of Participants With a ≥1% Increase in Glycosylated Hemoglobin A1c (HBA1c) | 80 | 111 |
A blood sample was collected that was sent to a laboratory for an anti-relamorelin antibody screening test. A positive screening test was confirmed by an immunodepletion assay. The number of participants in each of the following categories are reported: Negative Screening Test, Positive Screening Test, Negative Confirmatory Test, and Positive Confirmatory Test at each time point.
| Participants | Relamorelin 10 μg |
|---|---|
| Screening Test (Baseline) — Negative | 127 |
| Screening Test (Baseline) — Positive | 18 |
| Confirmatory Test (Baseline) — Negative | 12 |
| Confirmatory Test (Baseline) — Positive | 0 |
| Screening Test (Day 14) — Negative | 115 |
| Screening Test (Day 14) — Positive | 18 |
| Confirmatory Test (Day 14) — Negative | 13 |
| Confirmatory Test (Day 14) — Positive | 0 |
| Screening Test (Day 28) — Negative | 104 |
| Screening Test (Day 28) — Positive | 17 |
| Confirmatory Test (Day 28) — Negative | 12 |
| Confirmatory Test (Day 28) — Positive | 0 |
| Screening Test (Day 84) — Negative | 87 |
| Screening Test (Day 84) — Positive | 17 |
| Confirmatory Test (Day 84) — Negative | 11 |
| Confirmatory Test (Day 84) — Positive | 1 |
| Screening Test (End of Treatment) — Negative | 6 |
| Screening Test (End of Treatment) — Positive | 1 |
| Confirmatory Test (End of Treatment) — Negative | 1 |
| Confirmatory Test (End of Treatment) — Positive | 0 |
| Screening Test (Unscheduled) — Negative | 6 |
| Screening Test (Unscheduled) — Positive | 0 |
| Positive Confirmatory Test (Unscheduled) — Negative | — |
| Positive Confirmatory Test (Unscheduled) — Positive | — |
Collected over Up to approximately 16 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/155 (0%) | 6/152 (3.9%) | 14/152 (9.2%) |
| Relamorelin 10 μg | 0/156 (0%) | 8/155 (5.2%) | 13/155 (8.4%) |
| Event | Placebo | Relamorelin 10 μg |
|---|---|---|
| Vaginal haemorrhageReproductive system and breast disorders | 0/109 | 1/113 |
| Cardiac failure congestiveCardiac disorders | 1/152 | 1/155 |
| InfluenzaInfections and infestations | 1/152 | 0/155 |
| SepsisInfections and infestations | 1/152 | 0/155 |
| Upper respiratory tract infectionInfections and infestations | 1/152 | 0/155 |
| DehydrationMetabolism and nutrition disorders | 1/152 | 1/155 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 1/152 | 1/155 |
| MalnutritionMetabolism and nutrition disorders | 1/152 | 0/155 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 1/152 | 0/155 |
| HeadacheNervous system disorders | 1/152 | 0/155 |
| Event | Placebo | Relamorelin 10 μg |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 9/152 | 5/155 |
| Urinary tract infectionInfections and infestations | 5/152 | 9/155 |
Intent-to-treat (ITT) Population included all randomized participants.
| Age, Continuous(years) | Placebo | Relamorelin 10 μg | Total |
|---|---|---|---|
| Mean | 54.1 ± 12.13 | 55.8 ± 12.07 | 55.0 ± 12.11 |
| Sex: Female, Male(Participants) | Placebo | Relamorelin 10 μg | Total |
|---|---|---|---|
| Female | 112 | 114 | 226 |
| Male | 43 | 42 | 85 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Relamorelin 10 μg | Total |
|---|---|---|---|
| Hispanic or Latino | 54 | 51 | 105 |
| Not Hispanic or Latino | 101 | 105 | 206 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Relamorelin 10 μg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 4 | 7 | 11 |
| Asian | 1 | 2 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 25 | 17 | 42 |
| White | 123 | 127 | 250 |
| More than one race | 2 | 3 | 5 |
| Unknown or Not Reported | 0 | 0 | 0 |
Showing the first 100 of 240 sites across 15 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2018 to primary completion in Jul 2020, 29 months.
Results were first posted in Aug 2021, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Relamorelin